KALEIGH WEEMS: Open Payments
NPI 1710605241 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,860 in 166 payments from 14 companies in 2025. Trend: 2023 $828 · 2024 $409 · 2025 $2,860
Food & beverage: $2,739Education: $121
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $495 |
| E.R. Squibb & Sons, L.L.C. | 19 | $403 |
| Teva Pharmaceuticals USA, Inc. | 16 | $317 |
| Janssen Pharmaceuticals, Inc | 14 | $259 |
| Alkermes, Inc. | 12 | $215 |
| ABBVIE INC. | 19 | $206 |
| Axsome Therapeutics, Inc. | 20 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $167 |
| Lundbeck LLC | 8 | $139 |
Products named: REXULTI, COBENFY, Auvelity, ARISTADA, VRAYLAR, CAPLYTA, TRINTELLIX, ABILIFY ASIMTUFII.
Industry payments across MO — which companies pay providers there.
